000112075 001__ 112075
000112075 005__ 20240319081001.0
000112075 0247_ $$2doi$$a10.5534/wjmh.210178
000112075 0248_ $$2sideral$$a127889
000112075 037__ $$aART-2022-127889
000112075 041__ $$aeng
000112075 100__ $$0(orcid)0000-0003-0178-4567$$aBorque Fernando, Á.$$uUniversidad de Zaragoza
000112075 245__ $$aTestosterone recovery after androgen deprivation therapy in prostate cancer: building a predictive model
000112075 260__ $$c2022
000112075 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112075 5203_ $$aPurpose: To analyze the variability, associated actors, and the design of nomograms for individualized testosterone recovery after cessation of androgen deprivation therapy (ADT). Materials and Methods: A longitudinal study was carried out with 208 patients in the period 2003 to 2019. Castrated and normogonadic testosterone levels were defined as 0.5 and 3.5 ng/mL, respectively. The cumulative incidence curve described the recovery of testosterone. Univariate and multivariate analyzes were performed to predict testosterone recovery with candidate prognostic factors prostate-specific antigen at diagnosis, clinical stage, Gleason score from biopsy, age at cessation of ADT, duration of ADT, primary therapy and use of LHRH (luteinizing hormone-releasing hormone) agonists. Results: The median follow-up duration in the study was 80 months (interquartile range, 49–99 mo). Twenty-five percent and 81% of patients did not recover the castrate and normogonadic levels, respectively. Duration of ADT and age at ADT cessation were significant predictors of testosterone recovery. We built two nomograms for testosterone recovery at 12, 24, 36, and 60 months. The castration recovery model had good calibration. The C-index was 0.677, with area under the receiver operating characteristic curve (AUC-ROC) of 0.736, 0.783, 0.782, and 0.780 at 12, 24, 36, and 60 months, respectively. The normogonadic recovery model overestimated the higher values of probability of recovery. The Cindex was 0.683, with AUC values of 0.812, 0.711, 0.708 and 0.693 at 12, 24, 36, and 60 months, respectively. Conclusions: Depending on the age of the patient and the length of treatment, clinicians may stop ADT and the castrated testosterone level will be maintained or, if the course of treatment has been short, we can estimate if it will return to normogonadic levels.
000112075 536__ $$9info:eu-repo/grantAgreement/ES/DGA/E46-20R$$9info:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033$$9info:eu-repo/grantAgreement/ES/MICINN/PID2020-116873GB-I00$$9info:eu-repo/grantAgreement/ES/MINECO/MTM2017-83812-P
000112075 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000112075 590__ $$a4.8$$b2022
000112075 591__ $$aUROLOGY & NEPHROLOGY$$b15 / 88 = 0.17$$c2022$$dQ1$$eT1
000112075 591__ $$aANDROLOGY$$b1 / 8 = 0.125$$c2022$$dQ1$$eT1
000112075 594__ $$a8.8$$b2022
000112075 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112075 700__ $$aEstrada-Domínguez, F.
000112075 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban, L. M.
000112075 700__ $$0(orcid)0000-0002-0586-8138$$aGil Sanz, M. J.$$uUniversidad de Zaragoza
000112075 700__ $$0(orcid)0000-0002-6474-2252$$aSanz, G.$$uUniversidad de Zaragoza
000112075 7102_ $$12007$$2265$$aUniversidad de Zaragoza$$bDpto. Métodos Estadísticos$$cÁrea Estadís. Investig. Opera.
000112075 7102_ $$11013$$2817$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Urología
000112075 773__ $$g40 (2022), e33 [13 pp.]$$pWorld j. men's health$$tThe world journal of men's health$$x2287-4208
000112075 8564_ $$s780438$$uhttps://zaguan.unizar.es/record/112075/files/texto_completo.pdf$$yVersión publicada
000112075 8564_ $$s2486592$$uhttps://zaguan.unizar.es/record/112075/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112075 909CO $$ooai:zaguan.unizar.es:112075$$particulos$$pdriver
000112075 951__ $$a2024-03-18-14:08:40
000112075 980__ $$aARTICLE